On July 22, 2025, the US Food and Drug Administration (FDA) started accepting applications to participate in the Commissioner’s National ...

In 2023 the FDA published guidance on rare diseases. The guidance recognises that many rare diseases are serious conditions ...

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

This week, the U.S. Food and Drug Administration (FDA) posted additional information on its recently announced “Commissioner's National ...

Senate Republicans are moving swiftly to clear key hurdles in their effort to pass a set of spending bills before the August recess and get the ball moving toward avoiding a government shutdown in ...

The majority of Teva's business lies in generic and off-patent branded drugs which faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...

The 2024 approvals included significant milestones in the biosimilar sector, with the FDA granting approval for the first biosimilar of Stelara, Wezlana and the first denosumab biosimilars, Wyost and ...

As a longtime Washington Post reporter and an author of 10 books, he held corporate America accountable for safe ...

When parts of the nervous system start to break down—or get broken—the consequences for human health can be staggering. Can ...

Immutep is continuing the AIPAC-003 trial, which enrolled 71 metastatic hormone receptor positive (HR+), HER2-negative/low or ...

Following a period of relative dormancy, research and development in the Alzheimer’s disease space is booming. And mounting attention, both in the development of disease modifying therapies (DMTs) and ...